Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130743 | 0.87 | MAOA (0.41) | MAOAMAOBKDM1AOPRL1ALDH1A1 | |
| SCHEMBL2989331 | 0.86 | SIGMAR1 (0.41) | MAOAMAOBOPRL1OPRM1OPRD1 | |
| SCHEMBL4125387 | 0.86 | SIGMAR1 (0.41) | MAOAMAOBOPRL1OPRM1OPRD1 | |
| SCHEMBL4118768 | 0.83 | TSHR (0.38) | MAOAMAOBLTA4HOPRL1 | |
| Bromide SCHEMBL10842432 | 0.75 | MAOA (0.44) | MAOAMAOBOPRL1OPRM1OPRD1 | |
| SCHEMBL4282683 | 0.72 | MAOA (0.36) | MAOAMAOBALDH1A1 | |
| SCHEMBL3412905 | 0.72 | GAA (0.46) | MAOAMAOBOPRM1OPRD1OPRK1 | |
| SCHEMBL28233336 | 0.72 | MAOA (0.33) | MAOAMAOBLTA4HKDM1AALDH1A1 | |
| SCHEMBL4112299 | 0.72 | TSHR (0.39) | MAOAMAOBOPRL1 | |
| SCHEMBL4873013 | 0.72 | SMN1; SMN2 (0.47) | LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| CN-101801927-A | Piperidine derivatives as nk3 receptor antagonists | HOFFMANN LA ROCHE | 2010-08-11 | — | — | CN | disclosed |
| EP-2200982-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | MAOA 1349/4885MAOB 1037/4885LTA4H 3216/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | MAOA 1349/4885MAOB 1037/4885LTA4H 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.